CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

453

Participants

Timeline

Start Date

February 23, 2015

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Acne Vulgaris
Interventions
DRUG

CD5789 (trifarotene)

Trial Locations (32)

2119

Galderma Investigational Site, Pécel

3529

Galderma Investigational Site, Miskolc

5000

Galderma Investigational Site, Szolnok

6720

Galderma Investigational Site, Szeged

7100

Galderma Investigational Site, Szekszárd

8230

Galderma Investigational Site, Balatonfüred

10117

Galderma Investigational Site, Berlin

10155

Galderma Investigational Site, New York

13507

Galderma Investigational Site, Berlin

15831

Galderma Investigational Site, Mahlow

27262

Galderma Investigational Site, High Point

30277

Galderma Investigational Site, Newnan

33027

Galderma Investigational Site, Miramar

33175

Galderma Investigational Site, Miami

36608

Galderma Investigational Site, Mobile

37922

Galderma Investigational Site, Knoxville

40241

Galderma Investigational Site, Louisville

42287

Galderma Investigational Site, Wuppertal

44122

Galderma Investigational Site, Beachwood

48149

Galderma Investigational Site, Münster

72758

Galderma Investigational Site, Rogers

86179

Galderma Investigational Site, Augsburg

87107

Galderma Investigational Site, Albuquerque

92123

Galderma Investigational Site, San Diego

95819

Galderma Investigational Site, Sacramento

97210

Galderma Investigational Site, Portland

430 04

Galderma Investigational Site, Chomutov

500 05

Galderma Investigational site, Hradec Králové

775 20

Galderma Investigational Site, Olomouc

532 03

Galderma Investigational Site, Pardubice

110 00

Galderma Investigational site, Prague

06847

Galderma Investigational Site, Dessau

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY